BioInformant

Your Global Leader in Stem Cell Market Research

MENUMENU
  • Blog
    • Interviews
  • News
  • Stem Cells
    • iPS Cells
    • MSCs
    • HSCs
    • Adipose SCs
    • Neural Stem Cells
  • Exosomes
  • CAR-T
  • Cord Blood
  • Shop
    • Products
    • Submit PR
    • Advertise
  • About
    • Testimonials
    • Story
    • Guarantee
    • Contact
  • Home
  • Blog
    • Stem Cells
      • HSCs
      • iPS Cells
      • MSCs
      • Neural Stem Cells
      • Adipose SCs
    • Exosomes
    • Cell Therapy
      • CAR-T
    • Cord Blood
    • Stem Cell News
    • Interviews
  • COVID-19
  • Shop
  • Submit PR
  • Company
    • Advertise
    • Testimonials
    • Story
    • Job Posts
    • Guarantee
    • Privacy Policy
    • Contact
Home » stem cell therapy » Page 2

4 Major Areas of Commercialization for iPS Cells

June 22, 2017 By Cade Hildreth (CEO) Leave a Comment

Commercializing iPS Cells

Since the discovery of induced pluripotent stem cells in 2006, a great deal of basic research has been done to understand how to produce, manipulate, and utilize the stem cell type.  In addition to this important basic research, a great deal of applied (“translational”) results has been done with the cell type. Induced pluripotent stem cells (also called iPS cells or iPSCs) are revolutionizing regenerative medicine because they represent a potential route for producing patient-specific stem cells for research or clinical use.

In the future, iPS cells will facilitate progress in personalized medicine by allowing a patient to use his or her own cells. In addition, iPSCs also show great promise in other areas, such as phamaco-toxicological screening, by allowing disease modeling and safety assessment of potential new drugs under development, in short, facilitating the study of a “disease in a dish.”

[Read more…]

Filed Under: iPS Cells, Stem Cells Tagged With: biobanking, cell therapy, drug development, iPSC, stem cell therapy, stem cells, toxicology screening

Market Brief – Opportunities and Threats within the Cord Blood Banking Industry

April 18, 2016 By Cade Hildreth (CEO) 1 Comment

Brief: Opportunities and Threats within the Cord Blood Banking Industry - Depositphotos_3306438_m-2015-e1460995483660.jpg

The cord blood banking industry is a complex industry, with numerous benchmarks that indicate the overall health of the industry, including public and private storage of cord blood and cord tissue units, utilization rates for cord blood, regional and global rates of hematopoietic stem cell transplantation (HSCT), and more.

Benchmarks are critical to assess, because the global cord blood market has matured substantially over the past few years, creating both serious threats and novel opportunities. Therefore, judging individual company performance relative to the broader cord blood marketplace has become substantially more complex.

Serious threats to the cord blood industry include:
[Read more…]

Filed Under: Cord Blood, Stem Cells Tagged With: cord blood, cord blood banking industry, HSCs, MSCs, stem cell therapy

No Longer Just for Humans — Cord Blood Banking Now Available to Horses Too

March 21, 2016 By Cade Hildreth (CEO) Leave a Comment

VetiCell Launches Veterinary Stem Cell Preservation Program - Red border collie dog and horse

VetiCell, LLC, has announced that it is launching a proactive stem cell storage program for animals, in which it will collect stem cells from the umbilical cord of horses or from the reproductive tissues of dogs following spay or neuter.

VetiCell is a sister company to AlphaCord, a human cord blood bank, with the two companies having the same owner and staff.

Currently, there are a couple companies operating in the veterinary stem cell market that collect stem cells through invasive methods (adipose or bone marrow). However, VetiCell’s new model is to collect veterinary stem cells without surgery from the umbilical cord of horses or from reproductive tissues after canine spay and neuter. These methods require no additional invasive surgery to collect an animal’s stem cells.

Since 2006, BioInformant has been tracking the human stem cell banking market. Initially, the market was focused  on the storage of umbilical cord blood, although it has expanded over the past ten years to include the storage of other types of stem cells, including those present within cord tissue, dental pulp, adipose tissue, and more.

With hundreds of human cord blood banks now competing worldwide, it will be interesting to see whether any of them add equine cord blood banking to their portfolio of human stem cell storage services.

[Read more…]

Filed Under: Cord Blood, HSCs, MSCs, Press Releases, Stem Cells Tagged With: dogs, horses, stem cell bank, stem cell therapy, veterinary, VetiCell

Transforming Stem Cell Research and Therapies – Minerva Discovers Naïve Stem Cell Growth Factor

February 23, 2016 By Cade Hildreth (CEO) Leave a Comment

Major Breakthrough for Stem Cell Research and Therapies – Minerva Discovers Naïve Stem Cell Growth Factor - Looking through microscope

In major news released last week, Minerva Biotechnologies announced a “major breakthrough for stem cell research and therapies – a simple method of inducing naïve state pluripotency in human stem cells.” While induced pluripotent stem cell (iPSC) techniques can reprogram an adult cell to a stem cell-like state, Minerva has discovered a “primitive growth factor, NME7-AB, that continues this reprogramming to an even earlier, embryonic-like point called the ‘naïve’ state.”

This finding is a continuation of ongoing innovation occurring in the area of stem cell research and applications.

To learn more, read the full press release below. [Read more…]

Filed Under: iPS Cells, Stem Cells Tagged With: Minerva Biotechnologies, stem cell therapy, stem cells

Aussie Stem Cell Company Cynata Therapeutics Signs LOI with apceth GmbH

December 17, 2015 By Cade Hildreth (CEO) Leave a Comment

Global Cooperation Australia’s Cynata Therapeutics to Partner with Germany’s apceth GmbH & Co. KG

Global Cooperation: Australia’s Cynata Therapeutics to Partner with Germany’s apceth GmbH & Co. KGCynata Therapeutics, an Australian stem cell company with a powerful mesenchymal stem cell (MSC) manufacturing technology, has signed a Letter of Intent (LOI) with the German giant,apceth GmbH & Co. a company developing genetically engineered, next generation mesenchymal stem cell (MSC) therapeutics.

This is a significant announcement, because apceth GmbH & Co. KG is an extremely well-funded group. Their major shareholders are the Strungmann family, which previously owned Hexal, one of the largest manufacturers of generic pharmaceuticals in Europe. While apceth GmbH & Co. KG is not widely known within the United States, it is a major force within the European Union (EU) biotech market.  [Read more…]

Filed Under: MSCs, Stem Cells Tagged With: apceth GmbH, cynata therapeutics, mesenchymal stem cells, stem cell, stem cell therapy

  • « Previous Page
  • 1
  • 2
  • 3
  • Next Page »

Nanocellect

Marathon Products

Let’s Get Social

  • Facebook
  • Twitter
  • LinkedIn
  • Pinterest
  • Instagram
Menu
  • Blog
  • Stem Cell News
    • Press Releases
  • Stem Cells
    • HSCs
    • iPS Cells
    • MSCs
    • Neural Stem Cells
    • Adipose SCs
  • Exosomes
  • Cell Therapy
    • CAR-T
  • Cord Blood
  • Interviews

Cart

Top Rated Products

  • Job Posting on BioInformant Job Posting on BioInformant.com - Your Perfect Hire Is In Our Audience
    Rated 0 out of 5
    $297
  • U.S. Cord Blood Banking Survey Cord Blood Banking Survey of U.S. Parents [2017]
    Rated 0 out of 5
    $197
  • Exosome Companies 2020 Global Database of Exosome Companies
    Rated 0 out of 5
    $149 $97
My Tweets

BioInformant's World-Class Clients

  • Submit Press Release
  • Advertise
  • Privacy and Terms

Copyright © 2022 · BIOINFORMANT, Your Global Leader in Stem Cell Market Research

| Email: Info@BioInformant.com | Phone: 703-859-7617 |

800 Corporate Drive, Suite 301, Stafford, VA 22554, United States

Disclaimer: All statements made on this website are NOT expressed as medical claims or advice. They are not intended to diagnose, treat, cure or prevent any disease or condition. If you have a health condition or concern, consult your physician or health care provider.